Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image: A clinician reviews pancreatic cancer imaging and oncology trial data as Phanes Therapeutics’ spevatamig Phase 2 results highlight the growing role of bispecific antibody research in first-line metastatic pancreatic ductal adenocarcinoma treatment.
Pharma & Biotech

Phanes Therapeutics’ spevatamig data puts cold-tumor immunotherapy back in focus at ASCO 2026

See how Phanes Therapeutics’ spevatamig data could reshape metastatic pancreatic cancer drug development after ASCO 2026.

Read More
Representative image showing retinal eye care and injectable ophthalmology treatment as Samsung Bioepis expands Europe’s aflibercept biosimilar market with the launch of OPUVIZ for major retinal diseases.
Pharma & Biotech

Can Samsung Bioepis reshape Europe’s retinal disease biosimilar market with OPUVIZ?

Find out how Samsung Bioepis’ OPUVIZ launch could reshape Europe’s aflibercept biosimilar market and ophthalmology access.

Read More
Representative image showing cardiovascular drug research and epigenetic silencing technology, reflecting Scribe Therapeutics’ STX-1150 strategy for long-lasting LDL-C reduction after a single dose.
Pharma & Biotech

Can Scribe Therapeutics make one-dose LDL-C lowering a practical CRISPR frontier?

Find out how Scribe Therapeutics’ STX-1150 could reshape long-acting LDL-C lowering through CRISPR-based epigenetic silencing.

Read More
Representative image showing a clinical skin examination for actinic keratosis, as Rubedo Life Sciences reports early RLS-1496 data suggesting lesion reduction with minimal irritation in a Phase 1b/2a dermatology study.
Pharma & Biotech

Rubedo takes cellular rejuvenation into actinic keratosis with early RLS-1496 results

Rubedo’s RLS-1496 shows early actinic keratosis lesion reduction with low irritation. Find out why Phase 2b matters next.

Read More
Representative image of an advanced mass spectrometry laboratory, highlighting how Thermo Fisher Scientific’s next-generation Orbitrap innovations at ASMS 2026 could support faster drug discovery, deeper proteomics research and the development of new therapies.
Pharma & Biotech

Why Thermo Fisher Scientific’s ASMS 2026 launch matters for drug discovery workflows

Thermo Fisher Scientific unveils new Orbitrap platforms at ASMS 2026. Find out how they could reshape drug discovery workflows today!

Read More
Representative image of radioligand therapy research for cancer-associated bone disease, highlighting how LIFT and NorthStar’s Lu-177-LT17 collaboration could advance targeted oncology treatment for bone lesions.
Pharma & Biotech

Can LIFT and NorthStar move Lu-177-LT17 into the next radioligand therapy frontier?

Find out how LIFT and NorthStar’s Lu-177-LT17 partnership could advance radioligand therapy for cancer bone disease today!

Read More
Representative image of breast cancer drug development, highlighting Avenzo Therapeutics’ ORION-1 trial of AVZO-023 and AVZO-021 in advanced HR+/HER2- metastatic breast cancer.
Pharma & Biotech

What Avenzo Therapeutics’ ORION-1 expansion reveals about the next phase of CDK drug development

Find out how Avenzo Therapeutics’ AVZO-023 and AVZO-021 combination study could influence HR+/HER2- breast cancer treatment.

Read More
Representative image of AI-powered digital pathology being used to analyse prostate cancer biopsy slides, reflecting Acupath Laboratories’ integration of the ArteraAI Prostate Test into its diagnostic workflow for localized prostate cancer risk stratification.
Medical Devices & Diagnostics

What Acupath’s ArteraAI Prostate Test rollout reveals about the next phase of precision oncology

Acupath adds ArteraAI Prostate Test to its pathology workflow. Find out what it means for AI prostate cancer risk stratification today.

Read More
Representative image of a clinical researcher reviewing rare disease therapy data, as Beren Therapeutics faces an extended FDA decision timeline for adrabetadex in infantile-onset Niemann-Pick disease type C.
Pharma & Biotech

Why the FDA extended its adrabetadex review and what it means for Beren Therapeutics

Adrabetadex faces a longer FDA review in infantile-onset NPC. The delay could shape rare-disease drug standards in 2026.

Read More
Representative image of AI-driven heart failure monitoring at home, showing how Coredio’s FDA breakthrough-designated platform could extend advanced cardiac assessment beyond hospital settings through wearables, blood pressure cuffs, and remote clinical review.
Medical Devices & Diagnostics

FDA breakthrough status gives Coredio’s AI heart failure platform a faster regulatory path

Coredio’s AI heart failure platform may bring hemodynamic insight into home care. See why FDA breakthrough status matters now.

Read More